Posted by Michael Wonder on 23 Jun 2024
Neurotech Pharmaceuticals receives priority review of biologics license application for NT-501 (revakinagene taroretcel) as a treatment for macular telangiectasia type 2
20 June 2024 - Priority review granted with a PDUFA goal date set for 17 December 2024.
Neurotech Pharmaceuticals announces that the US FDA has determined that the biologic license application for NT-501, an investigational encapsulated cell therapy for the treatment of macular telangiectasia type 2 is sufficiently complete to permit a substantive review.
